Search results
Found 2776 matches for
©
Credit: University of Oxford, John Cairns
Oxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time
9 June 2025
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
Elena Mitsi and Simon Drysdale appointed as Associate Professors by the University of Oxford
2 June 2025
We extend our congratulations to OVG colleagues, Elena Mitsi and Simon Drysdale, on their recent appointment as Associate Professors.
Study shows urgent change needed to reduce deaths from malaria and meningitis in comatose African children
28 April 2025
Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.
Oxford Vaccine Group Launches Novel Study on Relapsing Malaria
22 January 2025
The Oxford Vaccine Group has launched a novel clinical study, BIO-006, to investigate relapsing malaria infections caused by Plasmodium vivax. This unique parasite can remain dormant in the liver for months or years, reactivating to cause repeated malaria infections.
New Book Shines a Light on the Power of Pro-Vaccine Activism
20 January 2025
A new book by Professor Samantha Vanderslott of the University of Oxford, Pro-vax, is set to redefine how we think about vaccination by spotlighting a critical but often-overlooked force: pro-vaccine activism.
Oxford Vaccine Group Launches Study to Test Paratyphoid A Vaccine
15 January 2025
The Oxford Vaccine Group has launched a new clinical study, BiVISTA, to evaluate an experimental combination vaccine aimed at preventing enteric fever a disease caused by two different types of Salmonella bacteria, typhoid and paratyphoid.
Ineos Oxford Institute makes award to OVG project tackling antimicrobial resistance
25 October 2024
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over £2m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
New campaign launched to encourage vaccine uptake
30 September 2024
Parents are being urged to get their children vaccinated as experts launch a campaign to boost uptake in the UK amid rising cases of whooping cough and measles. Researchers at the Oxford Vaccine Group, which is part of the University of Oxford, have developed an animation that, they say, focuses on the "critical role" whooping cough jabs play in protecting against infection, which can cause serious complications such as pneumonia.
Ground-breaking research revealed in new video
17 September 2024
The Oxford Vaccine Group has released new footage of ground-breaking research aimed at revolutionising vaccine design, particularly for those most vulnerable to diseases like flu and COVID-19.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
Professor Teresa Lambe OBE elected to the Fellowship of the Academy of Medical Sciences
21 May 2024
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
More babies could die if rates of vaccination against whooping cough don’t increase
17 May 2024
Babies and the most vulnerable are at risk of death if vaccination rates for whooping cough don't increase, according to experts at the University of Oxford.
Professor Sir Andrew Pollard elected to the Fellowship of the Royal Society
16 May 2024
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.
How the Information Security Office and the National Cyber Security Centre keeps Oxford's research secure post-pandemic
3 May 2024
Oxford University's Information Security Office (InfoSec) invited the NCSC to Oxford to thank them for the work they did that kept Oxford’s vaccine research secure.
Ground-breaking study reveals how COVID-19 vaccines prevent severe disease
3 May 2024
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
Oxford hosts Belgian vaccine experts
28 March 2024
Researchers from Oxford Vaccine Group and the Pandemic Sciences Institute welcomed a delegation of vaccine researchers from Belgium to further UK-Belgian collaboration on vaccine development and manufacture.
Advancing a malaria vaccine for better global health outcomes
20 March 2024
Professor Sue Ann Costa Clemens CBE, Chair of Global Health at the Department of Paediatrics and Head of Oxford Latam Research Group – a collaboration between Oxford and Brazil, aimed at strengthening our commitment to global health – met with His Excellency Antonio Patriota, Brazilian Ambassador to the UK, to discuss the co-development of a Malaria vaccine and advance public health outcomes in Brazil.
New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites
18 March 2024
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.